Amidst robust sales growth and operational enhancements, Pulmonx Corp (LUNG) demonstrates a strong start to 2024 with significant improvements in revenue and gross margins.
Pulmonx (LUNG) delivered earnings and revenue surprises of 16.28% and 7.52%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?